GeneDx Holdings Corp.·4

Mar 12, 5:25 PM ET

Saad Kareem 4

4 · GeneDx Holdings Corp. · Filed Mar 12, 2024

Insider Transaction Report

Form 4
Period: 2024-03-09
Saad Kareem
Chief Business Officer
Transactions
  • Exercise/Conversion

    Class A Common Stock

    2024-03-09+2,84127,308 total
  • Exercise/Conversion

    Restricted Stock Unit

    2024-03-092,84131,249 total
    Class A Common Stock (2,841 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
  • [F2]6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Documents

1 file
  • 4
    form4-03122024_090335.xmlPrimary